drugset / Trial / NCT02181712
Mesenchymal Stem Cell Therapy for Lung Rejection
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess the safety and feasibility of mesenchymal stem cells therapy in patients with transplant related bronchiolitis obliteran syndrome (BOS)
Timeline
- Start
- 2014-07
- Primary completion
- 2021-08-12
- Completion
- 2021-08-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mesenchymal stem cell | Cell therapy | 0.5 cells/kg | Intravenous |
| Subject | Mesenchymal stem cell | Cell therapy | 1 cells/kg | Intravenous |